Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 28 peer-reviewed journal articles Updated
Infectious Disease · Latent Tuberculosis

Will My Latent TB Become Active? Risk Factors Explained

At a Glance

For a healthy person, the lifetime risk of latent tuberculosis waking up and becoming active TB is 5% to 10%, with the highest risk in the first two years. This risk increases significantly if your immune system is weakened by conditions like HIV, diabetes, or certain medications.

In this answer

2 sections

01

Why Do the Bacteria Wake Up?

02

Weighing the Risks and Benefits of Treatment

If you have been diagnosed with latent tuberculosis infection (LTBI), the bacteria that cause tuberculosis are asleep (dormant) in your body. For a healthy person with a normal immune system, the overall lifetime risk of these bacteria waking up and causing active, contagious TB disease is about 5% to 10% [1][2]. About half of this risk occurs within the first two years after you are initially infected; after that, the risk drops significantly but never goes away entirely.

Understanding your specific risk is essential because it helps you and your doctor decide if taking preventive medication is the right choice for you [3].

Why Do the Bacteria Wake Up?

Your immune system is responsible for keeping the TB bacteria locked away in a dormant state [1]. If your immune system becomes weakened—whether by illness, medication, or aging—it may no longer be able to contain the bacteria, allowing them to multiply and make you sick [4].

When assessing your chances of developing active TB, doctors look for specific “triggers” that compromise your immune system.

Medical Conditions That Increase Risk

Certain health conditions can drastically increase the chances of latent TB becoming active:

  • HIV Infection: HIV weakens the immune system and is the strongest known risk factor for TB reactivation [5]. While a healthy person has a 5-10% lifetime risk, a person living with untreated HIV has a 7% to 10% risk every single year [5][6].
  • Diabetes: Having poorly controlled diabetes makes it harder for your body to fight infections, significantly increasing the risk of latent TB waking up [7][8].
  • Other Health Issues: Conditions like chronic kidney disease requiring dialysis, severe malnutrition (low body weight), or a history of smoking can compromise your lung defenses and overall immunity, raising your risk [6][9][10].
  • Lung Conditions: Silicosis (a lung disease caused by inhaling silica dust) is a major risk factor, increasing the chance of active TB by nearly three times [11]. Additionally, if your chest X-ray shows fibrotic changes (scarring from a past, unrecognized lung infection), doctors consider this a high-risk marker for future reactivation [12].

Medications That Suppress the Immune System

Treatments designed to suppress the immune system can inadvertently allow dormant TB to wake up.

  • TNF-alpha Inhibitors: These are biologic medications (such as adalimumab or infliximab) often used to treat autoimmune conditions like rheumatoid arthritis, psoriasis, or Crohn’s disease. They carry a very high risk of triggering TB reactivation [13][14]. Because of this risk, screening and preventive treatment for latent TB are mandatory before starting these drugs [15].
  • Other Immunosuppressants: High-dose corticosteroids (like prednisone), chemotherapy, and medications used to prevent organ rejection after a transplant also suppress the immune system and increase your risk [6]. (Note: Newer biologic drugs, like IL-17 inhibitors, do not seem to carry the same high reactivation risk, though monitoring is still advised [16][17].)

Aging and Immune Decline

As we age, our immune system naturally becomes less robust—a process known as immunosenescence. Older adults with latent TB face a higher risk of reactivation simply because their immune system may no longer be strong enough to keep the bacteria in check [18][12].

Weighing the Risks and Benefits of Treatment

Because latent TB causes no symptoms, deciding whether to take preventive medication involves balancing your personal risk of the TB waking up against the potential side effects of the medication [3].

Preventive therapy is highly effective at killing the dormant bacteria and drastically lowering your risk of future disease [19][20]. Treatment typically involves taking antibiotics—such as isoniazid, rifampin, or rifapentine—for anywhere from 3 to 9 months [21][22]. Today, shorter 3- or 4-month regimens are often preferred because they are easier to complete and generally have a better safety profile [21].

The most notable potential side effect of these medications is liver irritation (hepatotoxicity) [23][24]. While severe liver damage is rare, the risk of liver side effects, particularly with isoniazid, increases significantly as you get older [25][26]. To protect you, doctors will actively monitor your liver health through regular blood tests during your treatment [27].

What if I am healthy with no risk factors?
If you are completely healthy, have none of the risk factors listed above, and were not recently exposed to someone with active TB, your lifetime risk is closer to the 5-10% baseline [1]. In this situation, the recommendation for treatment depends heavily on your age and when you were infected:

  • Recent Infection: If you know you were exposed recently, or if you had a negative TB test within the last two years that has now turned positive, you are in the highest risk window. Treatment is almost always recommended [19][28].
  • Unknown Timing / Older Adults: If you have no idea when you were infected and are older, your doctor will carefully weigh your 5-10% lifetime risk against the increased risk of liver side effects [26]. Sometimes, observing without treatment is the safer option for older, healthy adults. Discuss your unique situation with your healthcare provider.

Common questions in this guide

What increases the risk of latent TB becoming active?
Latent TB can become active if your immune system weakens and can no longer keep the bacteria dormant. Major risk factors include untreated HIV, diabetes, severe malnutrition, kidney disease, aging, and medications that suppress the immune system.
When is latent TB most likely to wake up?
About half of the lifetime risk of latent TB becoming active occurs within the first two years after you are initially infected. Because of this high-risk window, doctors often strongly recommend preventive treatment for recent infections.
Do I need treatment for latent TB if I am completely healthy?
If you are healthy with no risk factors and an unknown time of infection, your lifetime risk of developing active TB is low. Your doctor will help you weigh this 5% to 10% risk against the potential side effects of preventive medication.
What medications can trigger latent TB to wake up?
Immunosuppressant drugs can inadvertently allow dormant TB bacteria to wake up. These include high-dose corticosteroids, chemotherapy, and biologic medications like TNF-alpha inhibitors used for conditions such as rheumatoid arthritis or Crohn's disease.
What are the side effects of preventive TB treatment?
The most notable potential side effect of preventive TB medications, such as isoniazid or rifampin, is liver irritation. Your doctor will monitor your liver health with regular blood tests during treatment, as the risk of liver issues increases with age.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given my current health and medications, what do you estimate my specific risk is for my latent TB waking up?
  2. 2.What are the potential side effects of preventive TB medications like rifampin or isoniazid, and how frequently will you monitor my liver health with blood tests during treatment?
  3. 3.Considering my age and medical history, do the benefits of a 3- or 4-month preventive treatment regimen outweigh the risks of liver side effects for me?
  4. 4.If I choose not to take preventive medication right now, what specific signs or symptoms should I watch for that might indicate the TB is becoming active?
  5. 5.Are there any lifestyle changes I can make, like improving my diabetes control or quitting smoking, that will lower my risk of TB reactivation?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

Does Ethambutol Cause Vision Problems? Risks & SymptomsDoes the BCG Vaccine Cause a False Positive TB Test?Does Tuberculosis Medication Affect Birth Control?How Long Are You Contagious After Starting TB Treatment?How Long After TB Exposure Do You Test Positive?How to Recover from TB Lung Scarring (PTLD)Is Tuberculosis Treatment Safe During Pregnancy?What Are the Signs of Liver Damage From TB Medication?What Are the Symptoms of TB Outside the Lungs?How is Multidrug-Resistant TB (MDR-TB) Treated?What is Directly Observed Therapy (DOT) for Tuberculosis?Why You Need a Sputum Culture After a TB Blood Test

References

References (28)
  1. 1

    Diagnosis and Management of Latent Tuberculosis Infection: Updates.

    Swain S, Kumar A, Vishwakarma VK, et al.

    Infectious disorders drug targets 2024; (24(4)):12-19 doi:10.2174/0118715265275319231124053615.

    PMID: 38031772
  2. 2

    Long-Term Case-Finding of Latent Tuberculosis Infection Among Household Contacts to Support Tuberculosis Elimination Efforts in Indonesia.

    Purba BB, Sembiring RJS, Sitorus FE, et al.

    Materia socio-medica 2025; (37(3)):243-249 doi:10.5455/msm.2025.37.243-249.

    PMID: 41623531
  3. 3

    Treatment of Latent Tuberculosis Infection.

    Tang P, Johnston J

    Current treatment options in infectious diseases 2017; (9(4)):371-379 doi:10.1007/s40506-017-0135-7.

    PMID: 29238270
  4. 4

    Screening and testing for latent tuberculosis infection among patients who are immunocompromised.

    Sierra CJ, Downs CA

    The Nurse practitioner 2022; (47(11)):32-39 doi:10.1097/01.NPR.0000884860.99026.ee.

    PMID: 36287735
  5. 5

    Urogenital tuberculosis - epidemiology, pathogenesis and clinical features.

    Muneer A, Macrae B, Krishnamoorthy S, Zumla A

    Nature reviews. Urology 2019; (16(10)):573-598 doi:10.1038/s41585-019-0228-9.

    PMID: 31548730
  6. 6

    Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries.

    Getahun H, Matteelli A, Abubakar I, et al.

    The European respiratory journal 2015; (46(6)):1563-76 doi:10.1183/13993003.01245-2015.

    PMID: 26405286
  7. 7

    Diabetes mellitus and latent tuberculosis infection: an updated meta-analysis and systematic review.

    Zhou G, Guo X, Cai S, et al.

    BMC infectious diseases 2023; (23(1)):770 doi:10.1186/s12879-023-08775-y.

    PMID: 37940866
  8. 8

    Prevalence of Latent Tuberculosis Infection and its Associated Factors Among Diabetic Patients Availing Primary Health Care in Terengganu State, Malaysia.

    Husain NF, Yusoff HM, Hassan NM, Aziz AA

    Oman medical journal 2023; (38(5)):e546 doi:10.5001/omj.2023.97.

    PMID: 38249131
  9. 9

    Influenza and the risk of active tuberculosis occurrence among individuals with latent tuberculosis infection: A national cohort study in South Korea (2015-2020).

    Lee J, Seo H, Kim D, et al.

    Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi 2024; (57(3)):437-445 doi:10.1016/j.jmii.2024.04.003.

    PMID: 38627123
  10. 10

    Smoking Exposure and the Risk of Latent Tuberculosis Infection: Results from NHANES 2011-2012.

    Hu X, Liu J, Shao Y, et al.

    Toxics 2024; (12(1)) doi:10.3390/toxics12010094.

    PMID: 38276728
  11. 11

    Mini-review: Silico-tuberculosis.

    Lanzafame M, Vento S

    Journal of clinical tuberculosis and other mycobacterial diseases 2021; (23()):100218 doi:10.1016/j.jctube.2021.100218.

    PMID: 33598569
  12. 12

    Incidence and risk factors of active tuberculosis among older individuals with latent tuberculosis infection: a cohort study in two high-epidemic sites in eastern China.

    Zhu P, Hao X, Wang W, et al.

    Frontiers in cellular and infection microbiology 2024; (14()):1332211 doi:10.3389/fcimb.2024.1332211.

    PMID: 38741890
  13. 13

    Safety in moderate-to-severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti-tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials.

    Puig L, Tsai TF, Bhutani T, et al.

    Journal of the European Academy of Dermatology and Venereology : JEADV 2020; (34(8)):1744-1749 doi:10.1111/jdv.16460.

    PMID: 32289190
  14. 14

    Disseminated Tuberculosis in a Psoriasis Patient under Adalimumab Treatment despite the Chemoprophylaxis of Latent Tuberculosis: A Case Report.

    Oh JH, Ham SP, Park HJ

    Annals of dermatology 2021; (33(1)):77-81 doi:10.5021/ad.2021.33.1.77.

    PMID: 33911816
  15. 15

    Tuberculosis and TNF-α inhibitors in children: how to manage a fine balance.

    Parigi S, Licari A, Manti S, et al.

    Acta bio-medica : Atenei Parmensis 2020; (91(11-S)):e2020009 doi:10.23750/abm.v91i11-S.10311.

    PMID: 33004779
  16. 16

    Safety of Interleukin Inhibitors in Psoriatic Patients with Latent Tuberculosis Infection Without Chemoprophylaxis: A Systematic Review.

    Li J, Xiang X, Wang Z, et al.

    Acta dermato-venereologica 2025; (105()):adv42081 doi:10.2340/actadv.v105.42081.

    PMID: 40026108
  17. 17

    Risk of tuberculosis reactivation with interleukin (IL)-17 and IL-23 inhibitors in psoriasis - time for a paradigm change.

    Nogueira M, Warren RB, Torres T

    Journal of the European Academy of Dermatology and Venereology : JEADV 2021; (35(4)):824-834 doi:10.1111/jdv.16866.

    PMID: 32790003
  18. 18

    Latent Tuberculosis Infection Status of Pregnant Women in Uganda Determined Using QuantiFERON TB Gold-Plus.

    Bongomin F, Ssekamatte P, Nattabi G, et al.

    Open forum infectious diseases 2021; (8(6)):ofab241 doi:10.1093/ofid/ofab241.

    PMID: 34113689
  19. 19

    Screening for Latent Tuberculosis Infection in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.

    Jonas DE, Riley SR, Lee LC, et al.

    JAMA 2023; (329(17)):1495-1509 doi:10.1001/jama.2023.3954.

    PMID: 37129650
  20. 20

    The Challenge of Latent TB Infection.

    Blumberg HM, Ernst JD

    JAMA 2016; (316(9)):931-3 doi:10.1001/jama.2016.11021.

    PMID: 27599327
  21. 21

    Treatment with isoniazid or rifampin for latent tuberculosis infection: population-based study of hepatotoxicity, completion and costs.

    Ronald LA, FitzGerald JM, Bartlett-Esquilant G, et al.

    The European respiratory journal 2020; (55(3)) doi:10.1183/13993003.02048-2019.

    PMID: 31980498
  22. 22

    Safety and Efficacy of Rifampin or Isoniazid Among People With Mycobacterium tuberculosis Infection and Living With Human Immunodeficiency Virus or Other Health Conditions: Post Hoc Analysis of 2 Randomized Trials.

    Campbell JR, Al-Jahdali H, Bah B, et al.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2021; (73(9)):e3545-e3554 doi:10.1093/cid/ciaa1169.

    PMID: 32785709
  23. 23

    Computational toxicology analysis of candidate drivers and pathways in HRZE-associated drug-induced liver injury.

    Lai Y, Yang X, Tian H, et al.

    Toxicology mechanisms and methods 2026; 1-17 doi:10.1080/15376516.2026.2670504.

    PMID: 42112673
  24. 24

    Drug-induced liver injury and anti-hepatotoxic effect of herbal compounds: a metabolic mechanism perspective.

    Rani J, Dhull SB, Rose PK, Kidwai MK

    Phytomedicine : international journal of phytotherapy and phytopharmacology 2024; (122()):155142 doi:10.1016/j.phymed.2023.155142.

    PMID: 37913641
  25. 25

    Acute Liver Failure Caused by Isoniazid during Preventive Treatment for Latent Tuberculosis: A Rare Autopsy Case Report.

    Yamazaki Y, Tominaga K, Arisaka T, et al.

    Internal medicine (Tokyo, Japan) 2025; (64(14)):2160-2164 doi:10.2169/internalmedicine.4720-24.

    PMID: 39694482
  26. 26

    Hepatotoxicity induced by isoniazid in patients with latent tuberculosis infection: a meta-analysis.

    Oscanoa TJ, Vidal X, Luque J, et al.

    Gastroenterology and hepatology from bed to bench 2023; (16(1)):448-457 doi:10.22037/ghfbb.v16i1.2685.

    PMID: 37070117
  27. 27

    Isoniazid toxicity and TB development during biological therapy of patients with psoriasis in Colombia.

    Cataño J, Morales M

    The Journal of dermatological treatment 2016; (27(5)):414-7 doi:10.3109/09546634.2016.1151857.

    PMID: 27003177
  28. 28

    Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial.

    Belknap R, Holland D, Feng PJ, et al.

    Annals of internal medicine 2017; (167(10)):689-697 doi:10.7326/M17-1150.

    PMID: 29114781

This page provides educational information about the risk of latent tuberculosis becoming active. It does not replace professional medical advice, and you should always consult your doctor to evaluate your personal risk factors and treatment options.

Get notified when new evidence is published on Tuberculosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.